Literature DB >> 6523430

Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis.

C Korninger, K Lechner, H Niessner, H Gössinger, M Kundi.   

Abstract

The fibrinolytic capacity of 121 patients with a history of venous thrombosis and/or pulmonary embolism was studied by venous occlusion technique, at earliest 3 months after the last thromboembolic episode. After discontinuation of oral anticoagulation treatment the clinical course of the patients was followed and new thromboembolic episodes were noted. During the observation period of 56 +/- 18.8 months 45 of 121 patients experienced recurrence of thrombosis. The recurrence-rate was significantly lower in patients with a post-occlusion ELT shorter than 60 min (4.8%/year) than in patients with an ELT longer than 60 min (10.3%/year). It is concluded that the fibrinolytic capacity is a useful parameter for determining the risk of recurrence in patients with venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6523430

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.

Authors:  A Uddhammar; S Rantapåå-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

2.  Recurrent thromboembolism as a hallmark of Cushing's syndrome.

Authors:  A La Brocca; M Terzolo; A Pia; P Paccotti; P De Giuli; A Angeli
Journal:  J Endocrinol Invest       Date:  1997-04       Impact factor: 4.256

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

4.  Decreased fibrinolytic capacity and increased von Willebrand factor levels as indicators of endothelial cell dysfunction in patients with lupus anticoagulant.

Authors:  T K Nilsson; E Löfvenberg
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

5.  von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.

Authors:  J H Jansson; T K Nilsson; O Johnson
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

6.  Tissue type plasminogen activator antigen and activity in sickle cell disease.

Authors:  R B Francis
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

7.  Fibrinolytic Activity of Blood and its Determinants in Healthy Medical Students.

Authors:  Nazeem I Siddqui; M Shoeb; S Bose
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 8.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

Review 9.  Thromboembolic complications associated with brain tumors.

Authors:  R E Sawaya; B L Ligon
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study.

Authors:  Ludwig Traby; Marietta Kollars; Lisbeth Eischer; Sabine Eichinger; Paul A Kyrle
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.